Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BCSP-1 (NGLPGPIGP) is a synthetic peptide sequence derived from human collagen type I, specifically designed to stimulate the repair and regeneration of bone and cartilage tissues. Developed by Millennium Biologics, the peptide mimics the cell-binding motifs of the extracellular matrix, promoting the attachment, proliferation, and osteogenic/chondrogenic differentiation of mesenchymal stem cells and progenitor cells. It is primarily utilized as a functional coating for ceramic bone graft substitutes or integrated into tissue engineering scaffolds to treat osteochondral defects and accelerate local bone healing. The peptide sequence is present in human collagen type I and acts as a biologic modality to improve the bioactivity of synthetic bone graft materials.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BCSP-1.